OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sherman Discusses MEK Inhibitors for Thyroid Cancer

October 22nd 2012

Steven I. Sherman, MD, from MD Anderson Cancer Center, discusses the clinical interest in MEK inhibitors for thyroid cancer and a broad range of other tumors that signal through the MAP kinase pathway.

Dr. Langer on Targeted Agents for Locally Advanced NSCLC

October 19th 2012

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

Dr. Nancy Lewis Discusses the Regorafenib CORRECT Trial

October 18th 2012

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.

Dr. Krychman on Treating Cancer-Related Sexual Issues

October 18th 2012

Michael L. Krychman, MD, Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine, discusses managing and treating sexual health concerns in cancer patients and survivors.

Karen Masino on Building a Survivorship Program

October 17th 2012

Karen Masino, from Ingalls Memorial Hospital, discusses the intricacies of developing a survivorship program.

Dr. Gralow Explains the Side Effects of Zoledronic Acid

October 17th 2012

Julie R. Gralow, MD, from Seattle Cancer Care Alliance, discusses the side effects associated with the administration of zoledronic acid.

Dr. James Mohler Discusses Androgen-Deprivation Therapy

October 16th 2012

James Mohler, MD, from Roswell Park Cancer Institute, discusses androgen-deprivation therapy, a standard treatment for men with metastatic prostate cancer.

Dr. Tripathy on the Updated EMILIA T-DM1 Trial Results

October 15th 2012

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the phase III EMILIA trial that examined the T-DM1 for women with HER2-positive breast cancer.

Rajni Kannan on the Side Effects of Yervoy and Zelboraf

October 12th 2012

Rajni Kannan discusses the importance patient education or managing the side effects associated ipilimumab and vemurafenib in metastatic melanoma.

Dr. Camidge on the Evolution of Clinical Cancer Research

October 11th 2012

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the ever changing and evolving world of clinical cancer research.

Dr. Petrylak on Enzalutamide's Role in Prostate Cancer

October 9th 2012

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Dr. Ribas on Combining Vemurafenib and Ipilimumab

October 9th 2012

Antoni Ribas, MD, from the UCLA Jonsson Comprehensive Cancer Center, discusses a phase I/II trial combining vemurafenib and ipilimumab for metastatic melanoma.

Dr. Sippel Explains Thyroid Cancer Risk Factors

October 2nd 2012

Rebecca S. Sippel, MD, from University of Wisconsin, explains the need for added screening for those at high-risk of developing thyroid cancer.

Dr. Weiner on the T-DM1 Mechanism of Action

October 1st 2012

Dr. Louis Weiner, from Lombardi Comprehensive Cancer Center, on the T-DM1 mechanism of action in HER2-positive breast cancer.

Dr. Kathleen Foley on the Goal for Cancer Pain Management

September 28th 2012

Kathleen M. Foley, MD, from Memorial Sloan-Kettering Cancer Center, on the history and future goals for cancer pain management.

Dr. Sherman on Sequencing Cabozantinib and Vandetanib

September 28th 2012

Dr. Eric Sherman, Memorial Sloan-Kettering Cancer Center, on the optimal sequencing of cabozantinib and vandetanib for patients with medullary thyroid cancer.

Dr. Garcia on Combination Therapy for Breast Cancer

September 27th 2012

Agustin A. Garcia, MD, from Keck School of Medicine of USC, discusses clinical trials that investigated combination therapy for treating advanced breast cancer.

Dr. Zelenetz Previews the 2012 ASH Annual Meeting

September 26th 2012

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, previews several trials that will likely be presented at the 54th annual ASH meeting.

Dr. Hammond Discusses HER2 Testing Guideline Revisions

September 20th 2012

Pathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.

Bonnie Addario Discusses the Stigma of Lung Cancer

September 19th 2012

Lung cancer survivor, Bonnie Addario, the founder of the Bonnie J. Addario Lung Cancer Foundation, discusses the prevalent stigma that lung cancer is a self-inflicted disease caused solely by smoking.